Altimmune (ALT) Cash from Financing Activities (2010 - 2026)

Altimmune (ALT) has 17 years of Cash from Financing Activities data on file, last reported at $78.5 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $78.5 million, up 130.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $251.2 million (up 465.45% YoY), and the FY2025 annual result was $206.8 million, up 1959.36% from the prior year.
• Cash from Financing Activities declined to $78.5 million in Q1 2026 per ALT's latest filing, from $81.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $81.1 million in Q4 2025 and troughed at -$302000.0 in Q1 2023.
• A 5-year average of $25.8 million and a median of $13.1 million in 2023 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 169295.35% in 2023 and fell as far as 109.49% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$43000.0 in 2022, then surged by 169295.35% to $72.8 million in 2023, then plunged by 86.14% to $10.1 million in 2024, then jumped by 704.46% to $81.1 million in 2025, then dropped by 3.27% to $78.5 million in 2026.
• Business Quant data shows ALT's Cash from Financing Activities at $78.5 million in Q1 2026, $81.1 million in Q4 2025, and $39.3 million in Q3 2025.